NOAC Costs Weigh Heavy In Europe, Unmet Needs Remain
Makers of novel oral anticoagulants need to work on gaining real world data to prove their worth to European payers, as their INR testing benefit gets lost in administration.
Makers of novel oral anticoagulants need to work on gaining real world data to prove their worth to European payers, as their INR testing benefit gets lost in administration.